RT Journal Article
SR Electronic
T1 TIGIT as a therapeutic target of HPV-positive head and neck squamous cell carcinomas
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.02.21266776
DO 10.1101/2021.12.02.21266776
A1 Le, Xiuning
A1 Dang, Minghao
A1 Hegde, Venkatesh L.
A1 Jiang, Bo
A1 Slay, Ravaen
A1 Xiao, Weihong
A1 Akagi, Keiko
A1 Fresquez, Joseph
A1 Marcelo, Kathrina L.
A1 Luo, Qianyun
A1 Sinha, Pragya
A1 Yanamandra, Ananta V.
A1 Dunn, Joe Dan
A1 Bell, Diana
A1 Williams, Michelle
A1 Parra, Edwin
A1 Goepfert, Ryan
A1 Lai, Stephen H.
A1 Gross, Neil
A1 Agrawal, Amit
A1 Reuben, Alexandre
A1 Myers, Jeffrey
A1 Curran, Michael A.
A1 Sastry, K. Jagannadha
A1 Wang, Linghua
A1 Gillison, Maura L.
YR 2021
UL http://medrxiv.org/content/early/2021/12/05/2021.12.02.21266776.abstract
AB The tumor immune microenvironment (TIME) of treatment-naïve, human papillomavirus-positive head and neck squamous cell carcinoma (HPV-positive HNSCC) was interrogated at single-cell level to identify influential immune checkpoints as therapeutic targets. Single-cell transcriptome profiling revealed enrichment of numerous cell-cell interactions mediated by TIGIT-PVR/NECTIN2 in the TIME of HPV-positive HNSCC versus normal tonsil. TIGIT was the most differentially upregulated immune checkpoint on clonally expanded CD8+ T cells and was abundant on antigen-experienced, tissue-resident memory CD8+ T cell and T-regulatory subsets. TIGIT ligands PVR/NECTIN1/2 were abundant on mature regulatory dendritic cells, immunosuppressive plasmacytoid DCs, and macrophages. TIGIT and PD-1 co-blockade in the mEER murine model of HPV-positive HNSCC significantly reduced tumor growth, improved survival, restored effector function of HPV16 E7-specific CD8+ T cells, natural killer cells, and DCs, and conferred tumor re-challenge protection. This immunogenetic analysis at single-cell resolution focusing on HPV-positive HNSCC identified TIGIT as a rational therapeutic target.Competing Interest StatementX.L. serves consulting, advisory roles for EMD Serono (Merck KGaA), AstraZeneca, Spectrum Pharmaceutics, Eli Lilly, Boehringer Ingelheim, Bristol-Myers Squibb, and Celgene; and receives research funding from Eli Lilly and Boehringer Ingelheim; M. W. serves advisory board roles for Roche and Bayer Pharmaceuticals; S.Y.L. serves as a medical affairs consultant for Cardinal Health; N.G. serves advisory board, consulting roles for Sanofi-Genzyme, Shattuck Labs, PDS Biotechnology, Intuitive Surgical- Consultant; and research funding from Regeneron; A.R. serves in the Scientific Advisory Board and has received honoria from Adaptive Biotechnologies; M.A.C. receives grant funding from ImmunoMet Inc.; honoraria/fees for consulting, lectures, speakers bureau, and/or other affiliations (e.g. advisory board) for ImmunoGenesis Inc., Alligator Bioscience Inc., ImmunOS Inc, Oncoresponse Inc., Pieris Inc., Nurix Inc., Aptevo Inc., Servier Inc., Kineta Inc., Salarius Inc., Xencor Inc., Agenus Inc., and Mereo; and patents on methods and composition for localized secretion of anti-CTLA-4 antibodies and anti-PD-L1 and -PD-L2 dual specificity antibodies; M.L.G. serves as consulting, advisory board roles for LLX Solutions, LLC (Pending), Sensei, Mirati Therapeutics, BioNTech AG, Shattuck Labs Inc., EMD Serono Inc., Debiopharm, Kura Oncology, Merck Co., Ipsen Biopharmaceuticals Inc., Bristol-Myers Squibb, Bicara Therapeutics, Bayer HealthCare Pharmaceuticals, Roche, Roche Diagnostics GmbH, Genocea Biosciences, Inc., NewLink Genetics Corporation, Aspyrian Therapeutics, TRM Oncology, Amgen Inc.,AstraZeneca Pharmaceuticals, and Celgene Corp.; and research funding from Genocea, BMS, Kura, Cullinan, Genentech, BioNtech, and Gilead. All remaining authors report no conflict.Funding StatementDr. Xiuning Le is supported by Stiefel Oropharyngeal Research Fund and ASCO Conquer Cancer Foundation. Dr. Linghua Wang is supported by start-up funds kindly provided by The University of Texas MD Anderson Cancer Center. This research was supported by the Oral Cancer Foundation, CPRIT, the Ohio State University, The University of Texas MD Anderson Cancer Center HPV-related Cancers Moonshot, and NCI Grant CA016672(ATGC) for The University of Texas MD Anderson Cancer Center Advanced Technology Genomics Core. Dr. Gillison is a CPRIT Scholar in Cancer Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of The University of Texas MD Anderson Cancer Center gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.